BLACKROCK SMALLER COMPANIES TRUST plc
All information is at 31 January 2011 and unaudited.
Performance at month end is calculated on a capital only basis
One Three One Three Five
Month Months Year Years Years
Net asset value 2.5% 15.6% 62.1% 60.0% 74.8%
Share price 6.4% 24.0% 78.1% 71.9% 77.9%
HGSC ex Inv Trust + AIM* 0.9% 9.9% 28.5% 11.7% 3.5%
Sources: BlackRock and DataStream
*With effect from 1 September 2007 the Hoare Govett Smaller Companies plus AIM
(ex Investment Companies) Index replaced the FTSE SmallCap Index (ex Investment
Companies) as the Company's benchmark. For the five year period the above index
has been blended to reflect this.
At month end
Net asset value Capital only (debt at par value): 607.60p
Net asset value Capital only (debt at fair value): 603.37p
Net asset value incl. Income (debt at par value): 613.38p**
Net asset value incl. Income (debt at fair value): 609.14p**
Share price: 531.50p
Discount to Capital only NAV (debt at par value): 12.5%
Discount to Capital only NAV (debt at fair value): 11.9%
Net yield: 1.1%
Total assets: £323.7m^
Gearing incl. Income: 9.9%
Ordinary shares in issue: 47,879,792^^
**includes net revenue of 5.78p.
^includes current year revenue.
^^excludes 2,113,731 shares held in treasury.
Ten Largest Sector
Weightings % of Total Assets
Software & Computer Services 9.6
Support Services 9.1
Industrial Metals & Mining 8.9
Oil & Gas Producers 8.8
Financial Services 8.7
Electronic & Electrical Equipment 8.1
Media 6.4
Industrial Engineering 5.9
Pharmaceuticals & Biotechnology 5.2
Chemicals 4.1
----
Total 74.8
====
Ten Largest Equity Investments (in alphabetical order)
Company
Abcam Group
Aveva Group
City of London Investment Group
Cove Energy
Domino Printing Sciences
Fidessa group
Hutchison China Meditech
IQE
ITE Group
Renishaw
Commenting on the markets, Mike Prentis, representing the Investment Manager
noted:
During January the Company's NAV per share rose by 2.5% on a capital only
basis, whilst the benchmark index increased by 0.9%. The FTSE 100 Index fell by
0.6%.
The main positive contributors to our outperformance in the month, relative to
the Company's benchmark, were our holdings in Mecom and Renishaw. Mecom
announced a trading update which highlighted its strong cash generation, even
though advertising revenues have yet to pick up. Renishaw produced very strong
interim results driven by high levels of demand from most parts of the world,
but especially China. Demand is for its metrology probes and related software
which is enabling customers to carry out measurements to far higher levels of
accuracy than possible using competitive equipment. Renishaw has continued to
invest heavily in R & D and we expect other product ranges to contribute
meaningfully to profits within the near future.
There was no significant negative contributor to relative performance during
the month, in that no one holding detracted from relative performance by more
than 0.25%.
Outperformance was derived from both stock selection and sector allocation. The
main positive sector contributor was our large overweight position in the
electronics and electrical equipment sector. Interestingly, the largest
negative contributor was our overweight position in the industrial engineering
sector; the companies in this sector have very similar drivers to those in the
electronics and electrical equipment sector. The main reason for the
underperformance of the industrial engineering sector would appear to be the
poor share price performance of stocks such as Rotork, Spirax Sarco and
Spectris during January. All of these companies had market capitalisations too
large to retain membership of the Hoare Govett indices when rebalanced on 1
January. We suspect they have experienced a wave of benchmark related selling,
but we remain confident that all continue to trade well; we have a holding in
each.
We sold the balance of our holding in Biocompatibles following the bid from
BTG. We also sold our holding in Hardy Underwriting on the grounds of likely
increasing claims for the sector and weak rate increases on renewal. We added
new holdings in Mulberry and Collins Stewart. We held meetings with the chief
executives of both companies before taking holdings. It is clear that demand
for Mulberry's upmarket leather handbags remains very strong, driven by demand
from wealthy Chinese and other overseas buyers. Whilst the stock is highly
valued we believe its brand, aimed at the luxury end of the international
market, is more likely than many to be enduring. Collins Stewart is a mix of
businesses. We believe its wealth management business has good long term growth
potential, its Hawkpoint corporate finance business could soon enter more
encouraging times for mergers and acquisitions at the smaller end of the market
and its broking business is gaining market share. The rating of the shares is
also modest.
16 February 2011
ENDS
Latest information is available by typing www.blackrock.co.uk/its on the
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV
terminal). Neither the contents of the Manager's website nor the contents of
any website accessible from hyperlinks on the Manager's website (or any other
website) is incorporated into, or forms part of, this announcement.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.